Rutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.
Rutika J. Mehta, MD, MPH
Advertisement
Articles by Rutika J. Mehta, MD, MPH
Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.
Rutika J. Mehta, MD, MPH, discusses how treatment has evolved in recent years for gastric and gastroesophageal junction cancers.
Advertisement
Latest Updated Articles
Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric CancerSeptember 8th 2020
Dr. Mehta on the Role of Biomarkers in Gastric CancerAugust 26th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
3
First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL
4
FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
5